Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Spyre Therapeutics’ chief legal officer sells $2.63m in shares

Spyre Therapeutics’ chief legal officer sells $2.63m in shares

Spyre Therapeutics' chief legal officer, Heidy King-Jones, disposed of approximately $2.63 million worth of shares on October 1, 2026. The sale comprised 28,933 shares of the company's common stock, priced between $89.24 and $93.46 per share. Despite the significant surge in Spyre Therapeutics' stock price, which has increased by 487% in the past year, some analysts believe the shares are currently overvalued.

In a related transaction, Ms. King-Jones also acquired 28,933 shares of common stock through the exercise of stock options, valued at around $419,528. The company's market capitalization is currently $7.93 billion, and it exhibits high volatility with a beta of 3. Ms. King-Jones now directly owns 2,845 shares of Spyre Therapeutics common stock and holds options to purchase an additional 482,478 shares, which vest over three years under certain conditions.

Recently, Spyre Therapeutics announced positive Phase II trial results for its SKYWAY-RA program, which evaluated the SPY072/TL1A treatment for rheumatoid arthritis. Analysts have given mixed ratings to the company, with some maintaining Buy ratings and others expressing more cautious sentiments.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

More in Finance & Markets

More from Saturday 3 October →